As I noted above, Biohaven has already submitted its NDA of Troriluzole for the treatment of patients with spinocerebellar ataxia to the FDA and was accepted for Priority Review. This is ...

Biohaven's clinical development program for troriluzole has spanned over eight years, including long-term safety data and the first large-scale, multi-center registrational trials in SCA.

Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...

Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of adult patients with spinocerebellar ataxia ...

Biohaven (NYSE:BHVN – Free Report) had its price objective lowered by Morgan Stanley from $69.00 to $63.00 in a research note released on Friday,Benzinga reports. The brokerage currently has an ...

Based on FDA Priority Review timelines and, if ultimately approved, Biohaven is prepared to commercialize troriluzole for SCA in the US in 2025. The Company had previously achieved positive ...

Troriluzole 200 mg dosed orally ... BHV-1300 and BHV-1310 are IgG degraders; Biohaven introduced next generation TRAPTM (Targeted Removal of Aberrant Protein) degraders, which are highly selective ...